QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.46

Change

+0.14 (+1.32)%

Market Cap

USD 2.09B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.13 (-0.47%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.39 (+0.78%)

USD 112.00B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 98.90B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.26 (-0.47%)

USD 92.14B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.25 (+1.39%)

USD 57.35B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.09 (-0.57%)

USD 53.27B
VUSA:F Vanguard Funds Public Limited ..

-0.65 (-0.64%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.94 (-0.92%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.02 (-0.21%)

USD 40.47B
0ZC:F Zscaler Inc

-2.88 (-1.64%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.11% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.11% 57% F 57% F
Trailing 12 Months  
Capital Gain 12.92% 58% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.92% 56% F 57% F
Trailing 5 Years  
Capital Gain 80.91% 89% A- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.91% 89% A- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 12.04% 87% B+ 79% B-
Dividend Return 12.04% 86% B+ 73% C
Total Return N/A 59% D- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 11.05% 56% F 80% B-
Risk Adjusted Return 108.92% 99% N/A 98% N/A
Market Capitalization 2.09B 85% B 68% D+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike